Melphalan may be a more potent leukemogen than cyclophosphamide.

@article{Greene1986MelphalanMB,
  title={Melphalan may be a more potent leukemogen than cyclophosphamide.},
  author={Mark H Greene and E. L. Harris and David M. Gershenson and George D. Malkasian and Lee Joseph Melton and A J Dembo and J. Michael Bennett and William Moloney and John Dunning Boice},
  journal={Annals of internal medicine},
  year={1986},
  volume={105 3},
  pages={360-7}
}
We have evaluated the relation between alkylating agents and leukemic disorders in 3363 1-year survivors of ovarian cancer who were treated in five randomized clinical trials and at two large medical centers. Overall, 28 patients developed acute nonlymphocytic leukemia (expected, 1.2) and 7 developed preleukemia. A 93-fold increased risk for acute nonlymphocytic leukemia was seen in 1794 women treated with chemotherapy; the incidence of leukemic disorders was 7.7/1000 women per year. Risk was… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
32 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…